Gene Therapy Drama: What’s Up at Sarepta?

Here’s the scoop: Sarepta just reported a third patient death linked to its gene therapy, sending its stock tumbling and making folks think twice about these new treatments. The company’s now switching gears—cutting jobs, dropping most gene therapy projects, and focusing on other medicines. If you’re following biotech stocks or just curious about the future of rare disease treatments, this is a reminder that medical breakthroughs can come with real risks and sudden pivots. #Business #Industry #GeneTherapy